ArticleFrontiers in immunology2024

A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression.

Maria Inmaculada Dominguez-Mozo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.